This biotech stock could be set to soar.

Medicine is rapidly changing and this biotech company is leading the change. Unsubscribe A Message from Huge Alerts Medicine is rapidly changing and this biotech company is leading the change. According to the World Health Organization, diabetes continues to be a huge constraint to global health and is one of the biggest causes of death worldwide, as more than 420 million people are currently diabetic. Big players in the Wall Street diabetes space include Merck & Co. and Abbott Laboratories. There’s a growing company falling under the radar that could soon hit the spotlight for its role in the diabetes care market. How? The Company harnesses the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. BSEM is focused on manufacturing products that change lives, leveraging its proprietary BioREtain processing method. BioREtain has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. Perinatal tissue allografts have been successfully used since the early 1900s as an alternative modality for the treatment for chronic wounds. More recently physicians have used these products to treat ocular surface disorders, chronic non-healing diabetic wounds, and in a variety of surgical procedures. The market for the company’s products has developed and is continuing to develop is extensive and this cutting-edge technology can prove to be a game-changer to many patients suffering from painful and slow recoveries. (OTC:BSEM)recently received approval of an Investigational Review Board (IRB) sanctioned clinical study that investigates the utilization and effects of its product in diabetic patients with foot ulcers.  This is a landmark study for the company and could put This stock on the map! Discover how data from this study could turn this company into the next biotech darling! Thank you for subscribing to DividendStocks.com's daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.   This message is a paid advertisement sent on behalf of Huge Alerts, a third-party advertiser of DividendStocks.com and MarketBeat.     This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency and Huge Alerts. American Consumer News, LLC dba MarketBeat receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $12,600. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Sideways Frequency or Huge Alerts. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts' website for additional information about the relationship between Huge Alerts and BioStem Technologies Inc. (OTC: BSEM).     If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com or leave us a voicemail at (844) 978-6257.   If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.   © 2006-2023 American Consumer News, LLC dba MarketBeat. 326 E 8th St #105, Sioux Falls, SD 57103. United States.   Today's Bonus Content: Elon Did It Again: This Could be Bigger than Tesla